Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 9:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 218 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Vehicle gel Clear all
Completed Phase 2 Interventional Results available

A Dose-ranging Study of DRM01 in Subjects With Acne Vulgaris

NCT02431052
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Olumacostat Glasaretil, Vehicle
Drug · Other
Lead sponsor
Dermira, Inc.
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
28
States / cities
Mobile, Alabama • Encino, California • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Sep 3, 2026, 9:29 AM EDT
Completed Phase 2 Interventional

Exploratory Study to Evaluate the Efficacy and Safety of CD07223 Gel in Subjects With Acne

NCT01106807
View directory record Official record
Conditions
Acne
Interventions
Epiduo vehicle gel, CD07223, Epiduo (adapalene and benzoyl peroxide) 0.1%/2.5% gel
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 35 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
9
States / cities
Hot Springs, Arkansas • Louisville, Kentucky • Warren, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 3, 2026, 9:29 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

A Study of Granexin® Gel for the Reduction of Scar Formation in Surgical Wounds Following Bilateral Anchor Incision Breast Surgery

NCT04331080
View directory record Official record
Conditions
Mammoplasty, Scarring, Scar, Breast Reconstruction
Interventions
Granexin® gel 100 μM, Granexin® gel 200 μM, Vehicle gel
Drug
Lead sponsor
Xequel Bio, Inc.
Other
Eligibility
18 Years and older · Female only
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
11
States / cities
Los Angeles, California • Pasadena, California • Doral, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2022 · Synced Sep 3, 2026, 9:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Exploratory Rectal Safety Study of Three Tenofovir Gel Formulations

NCT01575418
View directory record Official record
Conditions
HIV Prevention
Interventions
Rectal formulation (RF) of tenofovir 1% gel, Vaginal formulation (VF) of tenofovir 1% gel, Reduced glycerin vaginal formulation (RGVF) of tenofovir 1% gel, Radiolabeling of study drugs and semen
Drug · Radiation
Lead sponsor
Ian McGowan
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Sep 3, 2026, 9:29 AM EDT
Completed Phase 4 Interventional Results available

A Five Day Clinical Study to Examine the Effects of a Benzoyl Peroxide Treatment on Facial Acne Lesions

NCT02052752
View directory record Official record
Conditions
Skin Diseases
Interventions
3% Benzoyl Peroxide, 3% Benzoyl Peroxide Placebo, Neutrogena Rapid Clear®
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 45 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated May 17, 2015 · Synced Sep 3, 2026, 9:29 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA

NCT06393452
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
PP405 0.05% Topical Gel, PP405 Topical Vehicle Gel
Drug
Lead sponsor
Pelage Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
8
States / cities
Encinitas, California • Thousand Oaks, California • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Sep 3, 2026, 9:29 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris

NCT01974323
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Dapsone Gel, Dapsone Gel Vehicle
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
12 Years and older
Enrollment
2,238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Beverly Hills, California • Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Oct 8, 2018 · Synced Sep 3, 2026, 9:29 AM EDT
Not listed Phase 2Phase 3 Interventional

Safety and Efficacy of Pro-ocular™ 1% in Daily Scleral Lens Wearing Patients With Ocular Graft-versus-Host Disease

NCT04769648
View directory record Official record
Conditions
Ocular Graft-versus-host Disease
Interventions
Pro-ocular™ Topical Gel 1%, Placebo
Drug
Lead sponsor
Glia, LLC
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Needham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Sep 3, 2026, 9:29 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

BPX-01 Minocycline 1% Topical Gel for Reduction of Propionibacterium Acnes

NCT02709096
View directory record Official record
Conditions
Acne Vulgaris
Interventions
BPX-01, 1% Topical Gel, BPX-01 Vehicle Gel
Drug
Lead sponsor
BioPharmX, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Sep 3, 2026, 9:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Efficacy of Topical TolaSure on Skin Punch Biopsies in Healthy Participants

NCT03620175
View directory record Official record
Conditions
Wound Healing
Interventions
TolaSure Topical Gel
Drug
Lead sponsor
BioMendics, LLC
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Sep 3, 2026, 9:29 AM EDT
Not yet recruiting Phase 2 Interventional

Clinical Study to Evaluate the Safety and the Efficacy of EscharEx Drug Product (EX-03 Formulation) and Its Placebo Compared to Collagenase, Non-surgical Standard of Care, in Patients With Venous Leg Ulcers

NCT06690177
View directory record Official record
Conditions
Venus Leg Ulcers
Interventions
EscharEx (EX-03), Placebo (Gel vehicle)
Drug
Lead sponsor
MediWound Ltd
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Carlsbad, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Sep 3, 2026, 9:29 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

An Imaging Trial of the Distribution of Topical Gel Formulations in the Human Vagina

NCT00214747
View directory record Official record
Conditions
HIV Infections
Interventions
Vehicle gel formulations
Drug
Lead sponsor
Biosyn
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 24, 2005 · Synced Sep 3, 2026, 9:29 AM EDT
Not listed Not applicable Interventional

Dapsone Prurigo Study

NCT01870050
View directory record Official record
Conditions
Lichen Simples Chronicus and Prurigo
Interventions
Dapsone gel - verum
Drug
Lead sponsor
Cook County Health
Government
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Sep 3, 2026, 9:29 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Topical Acetaminophen for Itch Relief: a Proof of Concept Study in Healthy Subjects

NCT03997851
View directory record Official record
Conditions
Pruritus
Interventions
Acetaminophen, Carbomer 980
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Sep 3, 2026, 9:29 AM EDT
Terminated Phase 2 Interventional

Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa

NCT03578029
View directory record Official record
Conditions
Junctional Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa
Interventions
RGN-137, Placebo
Drug
Lead sponsor
Lenus Therapeutics, LLC
Industry
Eligibility
4 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
5
States / cities
Evanston, Illinois • Brooklyn, New York • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2022 · Synced Sep 3, 2026, 9:29 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Papulopustular Rosacea Study

NCT01493687
View directory record Official record
Conditions
Papulopustular Rosacea (PPR)
Interventions
CD5024, Azelaic acid 15% Gel
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
683 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
40
States / cities
Birmingham, Alabama • Rogers, Arkansas • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 3, 2026, 9:29 AM EDT
Terminated Phase 2 Interventional

Safety and Efficacy Study of MRE0094 to Treat Large, Single or Multiple, Chronic, Neuropathic, Diabetic Foot Ulcers

NCT00318214
View directory record Official record
Conditions
Foot Ulcer, Diabetic, Diabetes Complications
Interventions
MRE0094, Vehicle gel
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
19
States / cities
Phoenix, Arizona • Tucson, Arizona • Fresno, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 31, 2012 · Synced Sep 3, 2026, 9:29 AM EDT
Completed Phase 3 Interventional Results available

LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

NCT02786901
View directory record Official record
Conditions
Cataract, Pain, Ocular Inflammation
Interventions
Loteprednol Etabonate Ophthalmic Gel dosed TID, Loteprednol Etabonate Ophthalmic Gel dosed BID, Vehicle Gel
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
6
States / cities
Phoenix, Arizona • Oceanside, California • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Sep 3, 2026, 9:29 AM EDT
Completed Phase 4 Interventional Results available

A Study to Investigate the Use of Hydrogel Vehicle in Maintaining the Skin Barrier in Persons With Atopic Dermatitis

NCT01065714
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Hydrogel vehicle, Eucerin Lotion
Drug
Lead sponsor
Derm Research, PLLC
Other
Eligibility
12 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 24, 2013 · Synced Sep 3, 2026, 9:29 AM EDT
Not listed Phase 2 Interventional

A Trial to Evaluate the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratosis

NCT06108024
View directory record Official record
Conditions
Seborrheic Keratosis
Interventions
SM-020 gel 1.0%, Vehicle gel
Drug
Lead sponsor
DermBiont, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Coral Gables, Florida • New Brighton, Minnesota • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Sep 3, 2026, 9:29 AM EDT
Completed Phase 3 Interventional Results available

Bioequivalence Study of Two Treatments in the Treatment of Acne Vulgaris on the Face

NCT03393494
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene and Benzoyl Peroxide Topical Gel, Epiduo Topical Product, Placebo
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
12 Years to 40 Years
Enrollment
825 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 7, 2021 · Synced Sep 3, 2026, 9:29 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris

NCT01974141
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Dapsone Gel, Dapsone Gel Vehicle
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
12 Years and older
Enrollment
2,102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Encino, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2018 · Synced Sep 3, 2026, 9:29 AM EDT
Completed Phase 3 Interventional Results available

The Vaginal Health Trial

NCT02516202
View directory record Official record
Conditions
Atrophy of Vagina, Menopause, Dyspareunia (Female)
Interventions
Vagifem, Replens, Placebo tablet, Placebo gel
Drug · Device · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Minneapolis, Minnesota • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Sep 3, 2026, 9:29 AM EDT
Not listed Phase 2 Interventional

Efficacy and Safety of PR022 Topical Gel to Treat Mild-to-Moderate Atopic Dermatitis

NCT03351777
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PR022
Drug
Lead sponsor
Realm Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 20, 2017 · Synced Sep 3, 2026, 9:29 AM EDT